- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12.24 | Longeveron to Present at Biotech Showcase 2025 | 3 | GlobeNewswire (USA) | ||
| 13.11.24 | Longeveron reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.24 | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.11.24 | A Look Ahead: Longeveron's Earnings Forecast | 5 | Benzinga.com | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 11.11.24 | Longeveron ernennt Devin Blass zum neuen CTO | 2 | Investing.com Deutsch | ||
| 11.11.24 | Longeveron names Devin Blass as new CTO | 1 | Investing.com | ||
| 11.11.24 | Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) | 2 | GlobeNewswire (USA) | ||
| 04.11.24 | Peeling Back The Layers: Exploring Longeveron Through Analyst Insights | 1 | Benzinga.com | ||
| 27.10.24 | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 100 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 09.10.24 | Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 07.10.24 | Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day | 4 | GlobeNewswire (USA) | ||
| 02.10.24 | Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 1 | GlobeNewswire (USA) | ||
| 26.09.24 | BioMedNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa | 1 | iNVEZZ.com | ||
| 26.09.24 | Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa | 2 | GlobeNewswire (USA) | ||
| 26.08.24 | Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 15.08.24 | Longeveron reports Q2 results | 5 | Seeking Alpha | ||
| 15.08.24 | Earnings call: Longeveron reports progress on Lomecel-B, eyes FDA talks | 2 | Investing.com | ||
| 06.08.24 | Longeveron Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.07.24 | Longeveron surges 14% on phase 2 Lomecel-B Alzheimer's data | 3 | Seeking Alpha | ||
| 29.07.24 | Longeveron (LGVN) Stock Pops on Phase 2 Trial Updates | 2 | InvestorPlace |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 114,30 | -2,47 % | BioNTech Aktie: Geplante Maßnahmen und Strategien | Die BioNTech-Aktie zeigt sich in den ersten Januarwochen 2025 weitgehend stabil. Am Handelstag des 18. Januar verzeichnete das Papier einen leichten Rückgang von 0,74 Prozent auf 111,93 USD. Die Marktkapitalisierung... ► Artikel lesen | |
| CUREVAC | 3,664 | -3,43 % | Schock-News für CureVac Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| CRISPR THERAPEUTICS | 41,800 | -1,65 % | CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell? | ||
| OCUGEN | 0,780 | +4,49 % | Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema | MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene... ► Artikel lesen | |
| CYTODYN | 0,208 | 0,00 % | CytoDyn Inc.: December 2024 Letter to Shareholders | VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc. ("CytoDyn" or the "Company") achieved multiple crucial milestones... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,300 | +2,74 % | MEME-Coin Hype!: Kursexplosion und frische Allzeit-Hochs bei Solana! Mit dieser Aktie profitieren Sie sofort! | ||
| CELLECTIS | 1,588 | +1,15 % | Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 | UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs - one allogeneic... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 10,245 | +4,58 % | Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why | ||
| CERUS | 1,894 | +6,34 % | Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update | CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,177 | -13,28 % | WINT stock touches 52-week low at $0.21 amid sharp annual decline | ||
| APTEVO THERAPEUTICS | 4,365 | 0,00 % | Aptevo Therapeutics: Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 | Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise... ► Artikel lesen | |
| TRACON PHARMACEUTICALS | 1,410 | 0,00 % | TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces it Will Wind Down Operations | SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 1,720 | -6,01 % | Harvard Bioscience Aktie: Gewinnprognose erfreut! | Die Harvard Bioscience Aktie verzeichnete am 21. Dezember 2024 eine positive Entwicklung mit einem Anstieg von 0,48 Prozent auf 2,11 USD. Der Spezialist für biowissenschaftliche Technologien und Forschungsausrüstung... ► Artikel lesen | |
| ENTERA BIO | 2,480 | +5,08 % | Entera Bio Ltd.: Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates | JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of oral peptides and small therapeutic proteins, today reported... ► Artikel lesen | |
| XBRANE BIOPHARMA | 0,004 | -56,18 % | Xbrane Biopharma AB: Xbrane Biopharma appoints Jane Benyamin as acting Chief Financial Officer | Xbrane announces today that it has appointed Jane Benyamin as acting CFO as of January 9, 2025. As previously announced, the company's current CFO, Anette Lindqvist, is stepping down from the role of... ► Artikel lesen |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,19 % bei einem Aktienkurs von 1,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.
